IMGO Stock Overview
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Imago BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.01 |
| 52 Week High | US$36.09 |
| 52 Week Low | US$11.56 |
| Beta | 0 |
| 11 Month Change | 0.39% |
| 3 Month Change | 134.29% |
| 1 Year Change | 80.50% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 121.06% |
Recent News & Updates
Recent updates
Imago BioSciences (NASDAQ:IMGO) Is In A Good Position To Deliver On Growth Plans
Nov 08
Imago BioSciences GAAP EPS of -$0.41 beats by $0.09
Aug 12Here's Why We're Not Too Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Situation
Jul 26Companies Like Imago BioSciences (NASDAQ:IMGO) Are In A Position To Invest In Growth
Apr 12We're Not Very Worried About Imago BioSciences' (NASDAQ:IMGO) Cash Burn Rate
Dec 08Shareholder Returns
| IMGO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | 4.0% | 2.2% |
| 1Y | 80.5% | 18.3% | 32.6% |
Return vs Industry: IMGO exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: IMGO exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| IMGO volatility | |
|---|---|
| IMGO Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMGO's share price has been volatile over the past 3 months.
Volatility Over Time: IMGO's weekly volatility has increased from 18% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Hugh Rienhoff | www.imagobio.com |
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Imago BioSciences, Inc. Fundamentals Summary
| IMGO fundamental statistics | |
|---|---|
| Market cap | US$1.22b |
| Earnings (TTM) | -US$61.64m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-19.8x
P/E RatioIs IMGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMGO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$61.64m |
| Earnings | -US$61.64m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMGO perform over the long term?
See historical performance and comparison